CellaVision AB
Research CellaVision AB (CEVI) on Bullrun: valuation model: 21.7% undervalued, market cap SEK 3.23B, P/E 24.1, dividend yield 2.0%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCEVI
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryMedical Devices
- CurrencySEK
- Valuation signal21.7% undervalued
- Market capSEK 3.23B
- P/E24.1
- Dividend yield2.0%
- Financial periodFY2024
- RevenueSEK 723.22M
- Revenue growth6.8%
- Net incomeSEK 140.72M
- Free cash flowSEK 186.44M
- Gross margin67.3%
Valuation Snapshot
Bullrun's latest valuation model marks CellaVision AB as 21.7% undervalued; latest market cap is SEK 3.23B; P/E is 24.1; dividend yield is 2.0%.
About CellaVision AB
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials;
Frequently asked questions
Is CellaVision AB overvalued or undervalued?
Bullrun's valuation model currently marks CellaVision AB as 21.7% undervalued.
What is CellaVision AB's market cap?
CellaVision AB's market capitalization is SEK 3.23B.
What is CellaVision AB's P/E ratio?
CellaVision AB's price-to-earnings (P/E) ratio is 24.1.
Does CellaVision AB pay a dividend?
CellaVision AB has a dividend yield of 2.0%.
What does CellaVision AB do?
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems;